The US Food and Drug Administration (FDA) has concluded an inspection at Ajanta Pharma's manufacturing facility in Paithan, Maharashtra, which ended with the issuance of a Form 483 carrying five observations. According to reports from CNBC TV18, the inspection was conducted between April 13 and April 21, 2026. The company has stated it will respond to the observations within the stipulated timeline.
Shares of Ajanta Pharma Ltd. were trading largely flat on Wednesday, April 22, following the company's announcement. As reported by CNBC TV18, the stock was 0.16% lower at ₹2,786.80 on Wednesday. The stock has declined approximately 5% so far this year, reflecting investor concerns about the regulatory developments. However, as of April 21, 2026, the stock has shown recent improvement, trading at ₹2,791.2, which is ₹9.89 higher from the previous closing. The stock has fluctuated between ₹2,776 and ₹2,816 during the trading session, with a 3.81% return over the past year despite a -4.24% return in the last month.
The Form 483 issued by the USFDA represents a standard regulatory document that outlines observations made during an inspection. According to the company's statement, Ajanta Pharma will address these observations within the specified timeframe as part of its ongoing regulatory compliance efforts. The inspection results come as part of routine FDA oversight of pharmaceutical manufacturing facilities. This latest inspection adds to the company's regulatory history, which includes previous inspections with mixed results, including a no-observation inspection at the company's Dahej facility in April 2017.
Ajanta Pharma Limited is a specialty pharmaceutical formulation company established in 1973 with a mission of serving global healthcare needs worldwide. The company operates 7 state-of-the-art manufacturing facilities in India and Mauritius, with 2 facilities in India having USFDA approval. As of March 2026, the company has 5 operating subsidiaries overseas, including one step-down subsidiary. The company's business spans branded generics across India and more than 30 emerging countries in Africa, CIS, the Middle East and South East Asia, with strong presence in high-growth specialty segments including cardiology, dermatology, ophthalmology and pain management. The company has demonstrated consistent product development with 20 ANDAs awaiting approval from US FDA and has launched 25 new products in chronic therapies during 2025.
